Financial reports
ARS
2023 FY
Annual report to shareholders
5 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
3 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
27 Feb 24
8-K
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
27 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
6 Dec 23
8-K
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
28 Nov 23
8-K
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
17 Nov 23
8-K
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
2 Nov 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
8-K
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
2 Aug 23
8-K
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
5 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
424B5
Prospectus supplement for primary offering
6 Dec 23
424B5
Prospectus supplement for primary offering
4 Dec 23
S-3ASR
Automatic shelf registration
2 Nov 23
S-8
Registration of securities for employees
28 Feb 23
424B3
Prospectus supplement
26 Sep 22
S-8
Registration of securities for employees
24 Feb 22
S-8
Registration of securities for employees
25 Feb 21
424B5
Prospectus supplement for primary offering
25 Feb 21
Proxies
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
DEFA14A
Additional proxy soliciting materials
7 Apr 23
DEF 14A
Definitive proxy
7 Apr 23
DEFA14A
Additional proxy soliciting materials
18 Apr 22
DEFA14A
Additional proxy soliciting materials
8 Apr 22
DEF 14A
Definitive proxy
8 Apr 22
DEF 14A
Definitive proxy
15 Apr 21
DEFA14A
Additional proxy soliciting materials
2 Apr 20
DEF 14A
Definitive proxy
2 Apr 20
Other
UPLOAD
Letter from SEC
14 Nov 23
CORRESP
Correspondence with SEC
8 Nov 23
UPLOAD
Letter from SEC
13 Oct 23
EFFECT
Notice of effectiveness
13 Sep 19
CERT
Certification of approval for exchange listing
12 Sep 19
CORRESP
Correspondence with SEC
10 Sep 19
CORRESP
Correspondence with SEC
10 Sep 19
SEC STAFF
SEC staff action: Order
5 Sep 19
CORRESP
Correspondence with SEC
3 Sep 19
CORRESP
Correspondence with SEC
3 Sep 19
Ownership
4
Bhavesh Ashar
3 Apr 24
144
Notice of proposed sale of securities
1 Mar 24
4
Daniel Pichl
20 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Bhavesh Ashar
5 Feb 24
4
Daniel Pichl
5 Feb 24